Risk factors for adverse events within one year after atrial septal closure in children: a retrospective follow-up study

Gustaf Tanghöj1, Petru Liuba2-3, Gunnar Sjöberg4 and Estelle Naumburg1

1Department of Clinical Sciences, Unit of Pediatrics, Umeå University, Umeå, Sweden; 2Department of Cardiology, Pediatric Heart Center, Skåne University Hospital Lund, Lund, Sweden; 3Lund University, Lund, Sweden and 4Department of Women’s and Children’s Health, Karolinska Institute, Stockholm, Sweden

Abstract

Introduction: Secundum atrial septal defect is one of the most common congenital heart defects. Previous paediatric studies have mainly addressed echocardiographic and few clinical factors among children associated with adverse events. The aim of this study was to identify neonatal and other clinical risk factors associated with adverse events up to one year after closure of atrial septal defect. Methods: This retrospective case–control study includes children born in Sweden between 2000 and 2014 that were treated surgically or percutaneously for an atrial septal defect. Conditional logistic regression was used to evaluate the association between major and minor adverse events and potential risk factors, adjusting for confounding factors including prematurity, neonatal sepsis, neonatal general ventilatory support, symptomatic atrial septal defects, and pulmonary hypertension. Results: Overall, 396 children with 400 atrial septal defect closures were included. The median body weight at closure was 14.5 (3.5–110) kg, and the median age was 3.0 (0.1–17.8) years. Overall, 110 minor adverse events and 68 major events were recorded in 87 and 49 children, respectively. Only symptomatic atrial septal defects were associated with both minor (odds ratio (OR) = 2.18, confidence interval (CI) 95% 1.05–8.06) and major (OR = 2.80 CI 95% 1.23–6.37) adverse events. Conclusion: There was no association between the investigated neonatal comorbidities and major or minor events after atrial septal defect closure. Patients with symptomatic atrial septal defects had a two to four times increased risk of having a major event, suggesting careful management and follow-up of these children prior to and after closure.

A secundum atrial septal defect is located in the central portion of fossa ovalis and is one of the most common congenital heart defects.1 Moderate to large atrial septal defect is associated with significant left-to-right shunts and subsequent increase in pulmonary blood flow. This right-side volume overload of the heart may induce symptoms such as failure to thrive, tachypnoea, or recurrent infections.2,3 Haemodynamically significant atrial septal defects seldom present with symptoms and are preferably closed electively when the child has reached the age of three to four years.4-6 However, symptomatic atrial septal defects, especially combined with other cardiac or premature comorbidities, may need to be closed earlier. Today, there is no consensus concerning the timing of atrial septal defect closure among these children.

Six percent of all children born in Sweden are born preterm.6,7 Modern perinatal care has led to improved survival.8,9 Children born preterm have altered cardiac morphological structures as well as functional impairment of their heart, withstanding into adulthood, and sometimes along with additional cardiac and pulmonary sequelae.10-13 These cardiac alterations and comorbidities may influence these children’s vulnerability to complications when going through procedures later in life.

A shift towards an early atrial septal defect closure in young and small children with symptomatic atrial septal defects have been noted by us and others.3,14,15 Early atrial septal defect closure is considered safe and may be beneficial for pulmonary recovery in preterm children.16,17 However, few studies have assessed the association between the risk of adverse events following an atrial septal defect closure and preterm morbidity.

We hypothesised that preterm children are at risk for adverse events following atrial septal defect closure (surgical and percutaneous device closure) due to the complex comorbidity and additional cardiac remodelling. The main objective of this study was to explore potential neonatal and clinical factors associated with both major and minor events within 1 year after atrial septal defect closure.

Materials and methods

This is a retrospective case–control study including children under the age of 18 years who were born in Sweden and treated with an atrial septal defect closure (surgery or percutaneous device...
Table 1. Potential clinical risk factors and confounding factors

| Risk factors               | Grouped risk factors                                      |
|----------------------------|------------------------------------------------------------|
| Additional CHD             |                                                            |
| Chromosomal defects        |                                                            |
| Preterm                    |                                                            |
| Late premature             | Preterm >32 to <37 gestational age                         |
| Very premature             | Preterm <32 weeks of gestational age (Very preterm + extreme preterm) |
| Extreme premature          |                                                            |
| Pulmonary disease*         | Pulmonary diseases and general ventilatory support (Pulmonary disease + IRDS + BPD + Neonatal respiratory ventilation + Neonatal CPAP) |
| IRDS                       |                                                            |
| BPD                        |                                                            |
| Neonatal respiratory      |                                                            |
| ventilation                |                                                            |
| Neonatal sepsis            |                                                            |
| Pulmonary hypertension     |                                                            |
| Symptomatic ASD            | Symptomatic ASD                                            |

ASD = atrial septal defect; BPD = bronchopulmonary dysplasia; CHD = congenital heart defects; CPAP = continuous positive airway pressure; IRDS = infant respiratory distress syndrome.
*Pulmonary disease includes: Transient tachypnoea of the newborn, IRDS, BPD, Neonatal CPAP, Neonatal respiratory ventilation, Neonatal sepsis, Pulmonary hypertension, Symptomatic ASD.

Definitions of study group inclusion criteria and cases with conversion from percutaneous device closure to surgery

In 41 children who underwent atrial septal defect catheterisation with intention to treat the atrial septal defect, the procedure was converted to surgery due to unfavourable anatomy or insufficient rims. These children were included in the surgical group, and the conversion was not recorded as an adverse event.

In six children, major adverse events requiring surgery (persistent arrhythmias (n = 4), device embolisation (n = 1), and significant residual shunt (n = 1)) occurred after or during percutaneous device closure. These children required device removal and surgical closure of the defect. They were primarily included in the percutaneous device closure group, and the need of surgery was recorded as an adverse event and then additionally included in the surgical group.

Overall, 419 atrial septal defect closures were identified; 266 closed percutaneously and 153 surgically (Fig 1).

Statistical analyses

All data are presented as mean (SD), median (range), or percentage (%) depending on the type and distribution of the data. Continuous data were primarily tested for normality using Shapiro-Wilk test. Student’s t-test (unpaired two-sided) was used for parametrically distributed variables, Mann-Whitney U test for non-parametric distributed variables, and Person’s χ² for categorical data, with p < 0.05 considered to be significant.

Conditional logistic regression was performed to evaluate the association between major and minor adverse events and potential risk factors (Table 1). Maximum-likelihood estimates of the OR and 95% CI were obtained, taking into account potential confounding factors.

Univariate logistic regression was performed for both major and minor adverse events and performed for three categories:

1. All atrial septal defect closures
2. Children with percutaneous device closure of atrial septal defect
3. Children with surgical atrial septal defect closure

Conditional logistic regression was performed to evaluate the association between potential risk factors and major as well as minor adverse events following atrial septal defect closure. In this model, additional congenital heart defects and chromosomal defects were excluded as potential risk factors, and all potential synergistic congenital and clinical factors were grouped according to clinical relation (Table 1). This model was used to reduce the risk of overadjustment and to emphasise clinically linked risk factors.

Results

Overall, 511 children underwent atrial septal defect closure performed at either one of our two centres. A total of 117 children were excluded from the study group due to invalid identification numbers, having been born abroad or declined participation, leaving 394 individual children and 400 individual atrial septal defect closures for analysis (Fig 1).

General characteristics

The median body weight for children with an atrial septal defect closure was 14.5 kg (3.5–110 kg), the median age was 3.0 years
(0.1–17.8 years), the median atrial septal defect size 13.0 mm (4.1–37.0 mm), and the median atrial septal defect-to-weight ratio 0.9 mm/kg (0.1–4.3) (Table 2). The female:male ratio was 1.5:1. Further demographic data are presented in Table 3.

Adverse events

Overall, 110 minor adverse events in 87 children and 68 major events in 49 children were recorded. The most common major events were persistent arrhythmias or intraprocedural arrhythmias requiring treatment, accounting for 25 (36.7%) of all major events. Three types of minor events were predominantly common; 34 cases of suspected infection (30.9%), 32 cases with trivial pericardial/pleural effusion (29.1%), and 12 cases of arrhythmias not requiring treatment (10.9%) (Table 4).

Deaths

Four children died during the follow-up period. One 17-year-old child underwent an electrophysiological ablation one day prior to the atrial septal defect closure where a 27 mm Amplatzer septal occlude was used. She died on the 5th day after device placement due to device erosion and pericardial effusion. One child with surgical atrial septal defect closure, at the age of 13 months, died 237 days after surgery due to ventricular arrhythmia. A 12-month-old child with hypertrophic cardiomyopathy died 166 days after surgical atrial septal defect closure due to septic shock. One preterm child, born at a gestational age of 22 weeks, had a surgical atrial septal defect closure at the age of 6 months and died 27 days after surgery due to pulmonary hypertension crisis and multiple organ failure.

Associations between risk factors and adverse events. Univariate regression model and distribution

None of the sub-groups of premature birth were associated with neither minor nor major events, regardless of type of atrial septal defect closure (Table 3).

Some neonatal comorbidities that are common among children born prematurely were more common in cases with major events compared to controls. There were, for example, more cases with pulmonary disease (10 cases (22.2%) versus 34 controls (9.8%), p = 0.013), infant respiratory distress syndrome (IRDS) (6 cases (13.3%) versus 19 controls (5.5%), p = 0.042), need of neonatal respiratory ventilation (8 cases (17.8%) versus 13 controls (3.7%), p < 0.001), neonatal continuous positive airway pressure (CPAP) (12 cases (26.7%) versus 35 controls (10.1%), p < 0.001), and neonatal sepsis (6 cases (13.3%) versus 18 controls (5.2%), p = 0.031) (see Table 3).

Many of these factors also showed increased risks for adverse events in univariate regression analysis (see Table 3–5).

Especially among children with surgically closed atrial septal defect, risk factors such as neonatal pulmonary disease (OR = 4.90 CI 95% 1.62–14.84), bronchopulmonary dysplasia (OR = 5.10 CI 95% 1.07–24.10), need of neonatal respiratory ventilation (OR = 3.93 CI 95% 1.06–14.55), neonatal CPAP (OR = 2.75 CI 95% 1.01–7.47), symptomatic atrial septal defects (OR = 5.39 CI 95% 2.20–13.19), pulmonary hypertension (OR = 5.83 CI 95% 1.81–18.38), and additional congenital heart defects (OR = 2.27 CI 95% 1.02–5.05) were all associated with major adverse events in the univariate conditional regression analyses (Table 4).

Among children with percutaneously closed atrial septal defect, neonatal respiratory ventilation (OR = 6.16 CI 95% 1.47–25.80)
was associated with major events in univariate conditional regression analyses (Table 5).

**Associations between risk factors and adverse events. Multivariate adjusted regression model**

Neither premature birth, as a group or by gestational sub-groups, pulmonary diseases, general ventilatory support nor neonatal sepsis were associated with major events following atrial septal defect closure after adjusting for potential confounding factors (Table 6). Symptomatic atrial septal defects were associated with both major adverse events (OR = 2.80 CI 95% 1.23–6.37) and minor adverse events (OR = 2.18 CI 95% 1.05–8.06) following all types of atrial septal defect closure and adjusted for confounding factors. Among children with surgical atrial septal defect closure, symptomatic atrial septal defects were associated with major adverse events (OR = 4.50 CI 95% 1.47–13.80), taking into account potential confounding factors (Table 6).

**Discussion**

This is one of the first studies assessing neonatal risk factors’ association to adverse events after atrial septal defect closure. Some risk factors such as neonatal respiratory support as well as presence of pulmonary hypertension, additional congenital heart defects, pulmonary disease, and symptomatic atrial septal defects were associated with major adverse events following atrial septal defect closure in the univariate analyses. However, in the multivariate analysis, adjusted for potential confounding risk factors, this association was only present among children with symptomatic atrial septal defects. Hence, few or none of the neonatal factors seem to be associated with adverse events after atrial septal defect closure. Though preterm children are a heterogeneous group with multifactorial morbidity, our results are encouraging and an early indicated necessitous atrial septal defect closure can be regarded as safe in these children.

Few studies have previously described adverse events in small children after atrial septal defect closure. These studies have assessed several risk factors but have not included neonatal factors and comorbidities associated with preterm birth. The combination of cardiac alterations and neonatal morbidity may have an aggravating synergistic effect and potentially contribute to an increased risk of adverse events after atrial septal defect closure. It is well known that there are technical difficulties inherent in percutaneous device closure in smaller children, and thus surgical closure might have been the choice of preference in smaller children in our study. Further, a larger atrial septal defect-to-weight ratio is a known risk factor associated with adverse events in surgical closure. Our study supports these findings, as children with major events following all atrial septal defect closure were lighter, younger, and had a larger atrial septal defect-to-weight ratio compared to controls.

### Table 2. Study population

| Demography study population | Total individuals (n = 400) | Percutaneous device closure (n = 257) | Surgery (n = 143) | p* |
|-----------------------------|---------------------------|-------------------------------------|------------------|---|
| Gender (girls/boys)        | 245 (61.3%)/155 (38.8%)   | 161 (62.6%)/96 (37.4%)              | 84 (58.7%)/59 (41.3%) | 0.442 |
| Age at closure (years)      | 3.0 (0.1–17.8)            | 3.5 (0.3–17.5)                      | 2.5 (0.1–15.7)     | <0.001 |
| Weight at closure (kg)      | 14.5 (3.5–110)            | 15.1 (4.8–110.0)                    | 12.4 (3.5–67.0)    | <0.001 |
| ASD size (mm)              | 13.0 (4.1–37.0)           | 12.0 (4.1–30.0)                     | 13.5 (5.0–37.0)    | 0.042 |
| ASD-to-weight ratio         | 0.9 (0.1–4.3)             | 0.8 (0.1–2.5)                       | 1.1 (0.2–4.3)      | <0.001 |
| Gestational age at birth (weeks) | 38.5 (22.0–44.0) | 39.0 (23.0–43.0)                    | 38.0 (22.0–44.0)   | 0.758 |
| Additional CHD              | 111 (27.8%)               | 60 (23.3%)                          | 51 (35.7%)         | 0.008 |
| Chromosomal defect          | 45 (11.3%)                | 29 (11.3%)                          | 16 (11.2%)         | 0.977 |
| Premature (<37 weeks)      | 87 (21.8%)                | 56 (21.8%)                          | 31 (21.7%)         | 0.979 |
| Late premature (32 to <37 weeks) | 59 (14.8%) | 41 (16.0%)                          | 18 (12.6%)         | 0.363 |
| Very premature (28 to <32 weeks) | 13 (3.3%) | 8 (3.1%)                            | 5 (3.5%)           | 0.836 |
| Extreme premature (<28 weeks) | 15 (3.8%) | 7 (2.7%)                            | 8 (5.6%)           | 0.148 |
| Arrhythmias prior to ASD closure | 15 (3.8%) | 8 (3.2%)                            | 7 (4.9%)           | 0.390 |
| Pulmonary disease           | 45 (11.3%)                | 30 (11.7%)                          | 15 (10.6%)         | 0.737 |
| IRDS                        | 24 (6.0%)                 | 16 (6.2%)                           | 8 (5.6%)           | 0.799 |
| BPD                         | 17 (4.3%)                 | 10 (3.9%)                           | 7 (4.9%)           | 0.633 |
| Neonatal respiratory ventilation | 21 (5.3%) | 11 (4.3%)                           | 10 (7.0%)          | 0.215 |
| Neonatal CPAP               | 47 (11.8%)                | 27 (10.5%)                          | 20 (14.0%)         | 0.307 |
| Neonatal sepsis             | 24 (6.0%)                 | 15 (5.8%)                           | 9 (6.3%)           | 0.840 |
| Pulmonary Hypertension      | 33 (8.3%)                 | 19 (7.4%)                           | 14 (9.8%)          | 0.410 |
| Symptomatic ASD             | 47 (11.8%)                | 19 (7.4%)                           | 28 (19.6%)         | <0.001 |

ASD = atrial septal defect; BPD = bronchopulmonary dysplasia; CHD = congenital heart defects; CPAP = continuous positive airway pressure; IRDS = infant respiratory distress syndrome.

*p*Comparing percutaneous device closure with surgery.
| Risk factors associated with adverse events following all types of ASD closure. Univariate analysis. | Cases (major events) | Control (No major events) | p $X^2$ | OR (CI 95%) | Cases (minor events) | Control (No minor events) | p $X^2$ | OR (CI 95%) |
|---|---|---|---|---|---|---|---|---|
| Gender (girls/boys) | 33 (73.3%)/12 (26.7%) | 206 (59.0%)/143 (31.0%) | 0.176 | 0.58 (0.30–1.11) | 48 (55.8%)/38 (44.2%) | 197 (62.9%)/116 (37.1%) | 0.261 | 1.32 (0.82–2.12) |
| Age at closure (years) | 1.8 (0.1–16.8) | 3.2 (0.3–17.8) | 0.008 | 2.4 (0.4–17.8) | 3.2 (0.1–17.4) | 0.321 |
| Weight at closure (kg) | 11.0 (3.5–64.2) | 14.6 (4.5–110) | 0.007 | 12.6 (4.5–79.0) | 14.6 (3.5–110.0) | 0.333 |
| ASD size (mm) | 13 (5.0–37.0) | 12.3 (4.0–30.0) | 0.778 | 14.0 (5.0–37.0) | 12.0 (4.1–31.0) | 0.065 |
| ASD-to-weight ratio | 1.1 (0.3–2.7) | 0.8 (0.1–4.3) | 0.008 | 1.0 (0.1–4.3) | 0.8 (0.1–3.0) | 0.153 |
| Gestational age (weeks) | 38.0 (22.0–44.0) | 39.0 (23.0–23.0) | 0.067 | 38.0 (23.0–42.0) | 39.0 (22.0–43.0) | 0.765 |
| Additional CHD | 19 (42.2%) | 89 (25.5%) | 0.018 | 2.20 (1.20–4.08) | 27 (32.9%) | 81 (26%) | 0.208 | 1.43 (0.86–2.39) |
| Chromosomal defects | 5 (11.1%) | 38 (10.9%) | 0.964 | 1.37 (0.58–3.27) | 12 (14.6%) | 31 (9.9%) | 0.225 | 1.53 (0.77–3.09) |
| Preterm | 11 (24.4%) | 76 (21.8%) | 0.685 | 1.04 (0.51–2.14) | 19 (23.2%) | 68 (21.8%) | 0.789 | 1.00 (0.57–1.79) |
| Late premature | 4 (8.9%) | 55 (15.8%) | 0.197 | 0.49 (0.17–1.38) | 11 (13.4%) | 48 (15.4%) | 0.656 | 0.80 (0.40–1.61) |
| Very premature | 3 (6.7%) | 10 (2.9%) | 0.227 | 2.22 (0.60–3.27) | 3 (3.7%) | 10 (3.2%) | 0.840 | 1.08 (0.29–4.02) |
| Extreme premature | 4 (8.9%) | 11 (3.2%) | 0.096 | 2.74 (0.84–9.00) | 5 (6.1%) | 10 (3.2%) | 0.250 | 1.85 (0.61–5.56) |
| Pulmonary disease | 10 (22.2%) | 34 (9.8%) | 0.013 | 2.38 (1.09–5.20) | 9 (11.0%) | 35 (11.3%) | 0.943 | 0.91 (0.42–1.96) |
| IRDS | 6 (13.3%) | 19 (5.5%) | 0.042 | 2.43 (0.92–6.42) | 5 (6.1%) | 20 (6.4%) | 0.912 | 0.89 (0.32–2.45) |
| BPD | 4 (8.9%) | 13 (3.7%) | 0.151 | 2.30 (0.72–7.37) | 3 (3.7%) | 14 (4.5%) | 0.736 | 0.76 (0.21–2.71) |
| Neonatal respiratory ventilation | 8 (17.8%) | 13 (3.7%) | <0.001 | 5.04 (1.97–12.90) | 16 (5.2%) | 5 (6.1%) | 0.738 | 1.12 (0.47–3.15) |
| Neonatal CPAP | 12 (26.7%) | 35 (10.1%) | <0.001 | 2.92 (1.39–6.11) | 13 (15.9%) | 34 (10.9%) | 0.222 | 1.44 (0.745–3.57) |
| Neonatal sepsis | 6 (13.3%) | 18 (5.2%) | 0.031 | 2.57 (0.97–6.84) | 6 (7.3%) | 18 (5.8%) | 0.607 | 1.21 (0.47–2.86) |
| Pulmonary Hypertension | 8 (17.8%) | 24 (6.9%) | 0.012 | 3.06 (1.33–7.03) | 10 (12.2%) | 22 (7.1%) | 0.131 | 1.63 (0.745–3.57) |
| Symptomatic ASD | 13 (28.9%) | 33 (9.5%) | <0.001 | 3.86 (1.88–7.89) | 17 (20.7%) | 29 (9.3%) | 0.004 | 2.29 (1.20–4.39) |

ASD = atrial septal defect; BPD = bronchopulmonary dysplasia; CHD = congenital heart defects; CPAP = continuous positive airway pressure; IRDS = infant respiratory distress syndrome.
Table 4. Risk factors following ASD surgical repair

| Risk factors associated with adverse events following ASD surgical repair. Univariate analysis. | Cases (major events) | Control (No major events) | p χ² | OR (CI 95%) | Cases (minor events) | Control (No minor events) | p χ² | OR (CI 95%) |
|---|---|---|---|---|---|---|---|---|
| Gender (girls/boys) | 23 (71.9%)/9 (28.1%) | 61 (55.5%)/49 (44.5%) | 0.096 | 0.55 (0.24–1.28) | 35 (54.7%)/29 (45.3%) | 49 (62.8%)/29 (37.2%) | 0.327 | 1.37 (0.70–2.67) |
| Age at closure (years) | 1.5 (0.1–15.7) | 2.7 (0.4–13.6) | 0.206 | | 2.1 (0.4–15.7) | 2.7 (0.1–13.2) | 0.770 | |
| Weight at closure (kg) | 9.2 (3.5–61.5) | 12.6 (4.5–67.0) | 0.122 | | 12.3 (4.5–67.0) | 12.5 (3.5–53.0) | 0.652 | |
| ASD size (mm) | 14.0 (5.0–37.0) | 13.0 (6.0–28.0) | 0.855 | | 14.0 (5.0–37.0) | 13.0 (6.0–31.0) | 0.687 | |
| ASD-to-weight ratio | 1.1 (0.3–2.7) | 1.0 (0.2–4.3) | 0.335 | | 1.0 (0.2–4.3) | 1.1 (0.4–3.0) | 0.833 | |
| Gestational age (weeks) | 38.0 (22.0–44.0) | 39.0 (23.0–42.0) | 0.177 | | 38.0 (22.0–42.0) | 39.0 (23.0–42.0) | 0.756 | |
| Additional CHD | 16 (53.3%) | 34 (30.9%) | 0.023 | 2.27 (1.02–5.05) | 23 (36.5%) | 27 (35.1%) | 0.859 | 1.03 (0.52–2.06) |
| Chromosomal defects | 4 (13.3%) | 11 (10%) | 6.01 | | 10 (15.9%) | 5 (6.5%) | 0.074 | 2.18 (0.75–6.37) |
| Preterm | 6 (20.0%) | 25 (22.7%) | 0.750 | 0.79 (0.29–2.14) | 14 (22.2%) | 17 (22.1%) | 0.984 | 0.97 (0.44–2.19) |
| Late premature | 0 (0.0%) | 18 (16.4%) | 0.113 | | 8 (12.7%) | 10 (13.0%) | 0.960 | 0.95 (0.35–2.58) |
| Very premature | 2 (6.7%) | 3 (2.7%) | 0.291 | | 3 (4.8%) | 2 (2.6%) | 0.657 | 1.84 (0.30–11.35) |
| Extreme premature | 4 (13.3%) | 3 (3.6%) | 0.065 | 3.62 (0.90–16.24) | 3 (4.8%) | 5 (6.5%) | 0.730 | 0.70 (0.16–3.08) |
| Pulmonary disease | 8 (26.7%) | 7 (6.4%) | 0.002 | 4.90 (1.62–14.84) | 6 (9.5%) | 9 (11.8%) | 0.661 | 0.77 (0.26–2.29) |
| IRDS | 4 (13.3%) | 4 (3.7%) | 0.066 | 3.78 (0.90–16.09) | 3 (4.8%) | 5 (6.6%) | 0.729 | 0.70 (0.16–3.03) |
| BPD | 4 (13.3%) | 3 (2.8%) | 0.039 | 5.10 (1.07–24.10) | 2 (3.2%) | 5 (6.6%) | 0.456 | 0.46 (0.09–4.04) |
| Neonatal respiratory ventilation | 5 (16.7%) | 5 (4.5%) | 0.022 | 3.93 (1.06–14.55) | 4 (6.3%) | 6 (7.8%) | 1.00 | 0.79 (0.21–2.92) |
| Neonatal CPAP | 8 (26.7%) | 12 (10.9%) | 0.029 | 2.75 (1.01–7.47) | 11 (17.5%) | 9 (11.7%) | 0.332 | 1.56 (0.60–4.04) |
| Neonatal sepsis | 4 (13.3%) | 5 (4.6%) | 0.101 | 3.00 (0.76–11.62) | 3 (4.8%) | 6 (7.9%) | 0.455 | 0.54 (0.14–2.39) |
| Pulmonary hypertension | 7 (23.3%) | 6 (5.5%) | 0.003 | 5.83 (1.81–18.38) | 8 (12.7%) | 5 (6.5%) | 0.208 | 1.68 (0.55–2.87) |
| Symptomatic ASD | 13 (43.3%) | 14 (12.7%) | <0.001 | 5.39 (2.20–13.19) | 14 (22.2%) | 13 (16.9%) | 0.426 | 1.26 (0.55–2.87) |

ASD = atrial septal defect; BPD = bronchopulmonary dysplasia; CHD = congenital heart defects; CPAP = continuous positive airway pressure; IRDS = infant respiratory distress syndrome.
Table 5. Risk factors following all types of percutaneous device ASD closure

| Risk factors associated with adverse events following percutaneous device ASD closure. Univariate analysis. | Cases (major events) | Control (No major events) | p χ² | OR (CI 95%) | Cases (minor events) | Control (No minor events) | p χ² | OR (CI 95%) |
|-------------------------------------------------|-----------------------|---------------------------|-------|-------------|-----------------------|---------------------------|-------|-------------|
| Gender (girls/boys)                             | 13 (76.5%)/4 (23.5%)  | 148 (61.6%)/92 (38.4%)    | 0.302 | 0.49 (0.16-1.52) | 13 (59.0%)/9 (41.0%)  | 148 (62.9%)/87 (37.1%)    | 0.718 | 1.13 (0.47-2.71) |
| Age at closure (years)                          | 3.2 (0.4–16.8)        | 3.6 (0.3–17.8)            | 0.075 | 4.2 (0.5–17.8) | 3.5 (0.3–17.4)        | 0.375 |
| Weight at closure (kg)                          | 11.5 (4.8–64.3)       | 15.2 (5.1–110.0)          | 0.122 | 17.1 (5.6–79.4) | 15.1 (4.8–110)        | 0.457 |
| ASD size (mm)                                   | 12.0 (6.0–24.0)       | 12.0 (4.1–30.0)           | 0.621 | 14.0 (7.0–30.0) | 12.0 (4.1–27.0)       | 0.192 |
| ASD-to-weight ratio                             | 1.0 (0.3–1.7)         | 0.8 (0.1–2.5)             | 0.157 | 0.6 (0.1–2.5) | 0.8 (0.1–2.4)         | 0.365 |
| Gestational age (weeks)                         | 38.0 (28.0–42.0)      | 39.0 (23.0–43.0)          | 0.243 | 38.0 (24.0–41.0) | 39.0 (23.0–43.0)       | 0.463 |
| Additional CHD                                  | 3 (21.4%)             | 55 (23.0%)                | 0.891 | 1.40 (0.47–4.15) | 4 (22.2%)             | 54 (23.0%)                | 1.00  | 1.26 (0.47–3.37) |
| Chromosomal defects                             | 1 (7.1%)              | 27 (11.3%)                | 1.00  | 1.05 (0.23–4.85) | 2 (11.1%)             | 26 (11.1%)                | 0.630 | 1.27 (0.35–4.58) |
| Preterm                                         | 5 (35.7%)             | 51 (21.3%)                | 0.208 | 1.54 (0.52–5.58) | 5 (27.8%)             | 51 (21.7%)                | 0.550 | 1.06 (0.37–3.02) |
| Late premature                                  | 4 (28.6%)             | 37 (15.5%)                | 0.196 | 1.69 (0.52–5.46) | 3 (16.2%)             | 38 (16.2%)                | 0.556 | 0.82 (0.23–2.90) |
| Very premature                                  | 1 (7.1%)              | 7 (2.9%)                  | 0.370 | 2.08 (0.24–17.69) | 0 (0.0%)              | 8 (3.4%)                  | –     | –           |
| Extreme premature                                | 0 (0.0%)              | 7 (2.9%)                  | –     | –           | 2 (11.1%)             | 5 (2.1%)                  | 0.081 | 4.60 (0.83–25.24) |
| Pulmonary disease                               | 2 (14.3%)             | 27 (11.3%)                | 0.733 | 1.05 (0.23–4.85) | 3 (16.7%)             | 26 (11.1%)                | 0.443 | 1.27 (0.35–4.63) |
| IRDS                                           | 2 (14.3%)             | 15 (6.3%)                 | 0.240 | 2.00 (0.42–9.57) | 2 (11.1%)             | 15 (6.4%)                 | 0.345 | 1.47 (0.31–6.88) |
| BPD                                            | 0 (0.0%)              | 10 (4.2%)                 | –     | –           | 1 (5.6%)              | 9 (3.8%)                  | 0.529 | 1.20 (0.14–9.90) |
| Neonatal respiratory ventilation                | 2 (31.4%)             | 8 (3.4%)                  | 0.018 | 6.16 (1.47–25.80) | 1 (5.6%)              | 10 (4.3%)                 | 0.567 | 1.06 (0.13–8.70) |
| Neonatal CPAP                                   | 4 (28.9%)             | 23 (9.7%)                 | 0.050 | 2.89 (0.87–9.60) | 2 (11.1%)             | 25 (10.7%)                | 1.00  | 0.84 (0.18–3.79) |
| Neonatal sepsis                                 | 2 (14.3%)             | 13 (5.4%)                 | 0.197 | 2.33 (0.48–11.28) | 3 (16.7%)             | 12 (5.1%)                 | 0.080 | 2.93 (0.76–11.31) |
| Pulmonary hypertension                         | 1 (7.1%)              | 18 (7.6%)                 | 1.00  | 0.77 (0.10–6.12) | 2 (11.1%)             | 17 (7.3%)                 | 0.663 | 1.13 (0.28–5.62) |
| Symptomatic ASD                                 | 0 (0.0%)              | 19 (7.9%)                 | –     | –           | 3 (16.7%)             | 16 (6.8%)                 | 0.145 | 2.16 (0.59–8.08) |

ASD = atrial septal defect; BPD = bronchopulmonary dysplasia; CHD = congenital heart defects; CPAP = continuous positive airway pressure; IRDS = infant respiratory distress syndrome.
Table 6. Adjusted risk factors

|                         | All types of ASD closure | Percutaneous device closure | Surgery |
|-------------------------|--------------------------|-----------------------------|---------|
|                         | OR major events          | OR minor events             | OR major events | OR minor events | OR major events | OR minor events |
| Preterm >32 to <37 gestational age | 0.35 (0.10–1.18)        | 0.80 (0.37–1.76)            | 1.07 (0.27–4.27) | 0.92 (0.23–3.70) | –           | 0.78 (0.25–2.42) |
| Preterm <32 weeks of gestational age | 0.69 (0.18–2.68)        | 1.23 (0.34–4.45)            | 0.75 (0.06–9.98) | 1.43 (0.14–15.11) | 0.59 (0.03–12.66) | 1.48 (0.16–13.34) |
| Pulmonary diseases and general ventilatory support | 2.51 (0.83–7.64) | 1.04 (0.41–2.67) | 2.17 (0.46–10.15) | 0.53 (0.08–3.58) | 3.82 (0.28–52.00) | 1.45 (0.34–6.15) |
| Neonatal sepsis | 1.20 (0.34–4.31) | 0.77 (0.24–2.48) | 2.78 (0.48–16.22) | 3.10 (0.60–15.92) | 0.56 (0.07–4.54) | 0.25 (0.03–1.88) |
| Pulmonary hypertension | 1.32 (0.48–3.59) | 1.07 (0.43–2.68) | 0.75 (0.07–8.06) | 0.81 (0.14–4.86) | 2.50 (0.52–12.03) | 1.71 (0.43–6.82) |
| Symptomatic ASD | 2.80 (1.23–6.37) | 2.18 (1.05–4.52) | –           | 1.19 (0.39–8.42) | 4.50 (1.47–13.80) | 1.05 (0.39–2.80) |

ASD = atrial septal defect.

Preterm birth, regardless of gestational age group, was not associated with an increased risk of major adverse events following atrial septal defect closure.

Additional congenital heart defects, neonatal respiratory support, pulmonary comorbidity, and neonatal sepsis often have to be taken into consideration in the care of the preterm child. These factors were more common among cases with major events following atrial septal defect closure, but did not reach significance as risk factors in the adjusted model. Furthermore, the prematurely born children may suffer from reduced right ventricular function, altered pulmonary capillary bed maturation, and sub-clinical pulmonary hypertension.10,12,30,31 All this combined may contribute to increased risk of symptoms of atrial septal defect as well as adverse events following closure. None of the above risk factors, except for symptomatic atrial septal defects, were independently associated with adverse events after atrial septal defect closure when adjusted for potential confounding factors. This indicates that the altered morphological, global structural differences and functional impairment of the preterm child’s heart does not influence the risk of adverse events after atrial septal defect closure.10–13 Premature children with severe pulmonary comorbidity may however benefit from early atrial septal defect closure as has been suggested previously.14,32 Further studies identifying benefits of early atrial septal defect closure in this group of new survivors are needed.

Symptomatic atrial septal defects or clinically manifested heart failure has been reported to be present in 11.6–20% of children with atrial septal defect and even more common in children with large atrial septal defects.35,34 This is in line with our study, as 48 (12%) of the children had symptomatic atrial septal defects. This rules out the risk of selection bias due to overtreatment in our study. Children with symptomatic atrial septal defects were almost three times as common among children with major events (28.9 vs. 9.5%) and twice as common among children with minor events (20.7 vs. 9.8%) compared to controls in our study. Even after adjusting for potential confounding factors, the risk of major adverse events was almost three times as high and minor events twice as high in children with symptomatic atrial septal defects. This indicates that children with symptomatic atrial septal defects may carry a more severe morbidity compared to children with no symptoms. The bias for selection to surgical repair might be in favour for children with severe atrial septal defect morbidity, which in turn may increase the risk of major events in the surgical cases even after adjusting for all other factors.25,29 For complex and large atrial septal defect, surgical repair is still considered the most favourable method with long-term favourable outcomes.35

Significant arrhythmias occurred in 11 (22.9%) of all children in our study. This was more common among children with symptomatic atrial septal defects. Symptomatic atrial septal defects, often with an enlarged right ventricle caused by volume overload, may induce the same trigger to arrhythmias in cases of atrial septal defect closure as in other congenital heart defects such as tetralogy of Fallot.36 Thus, to decrease the risk of arrhythmias, these children might benefit from an early atrial septal defect closure.

This study is limited by the retrospective design, which may increase the risk of selection and recall bias. However, we believe that the risk of missing data due to incomplete registration in medical records and national registers is limited as we used both sources to retrieve demographic data, potential risk and confounding factors, and information on adverse events. Recent validation studies of the two registries in our study have found good coherence between the medical records and registries.37,38 Further, the number of included cases and controls in our study is substantial, which often increases the power in the conditional logistic analyses. However, since our study had cases with few adverse events, a risk of non-robust models was present.39 Thus, to reduce this risk, we grouped the similar potential synergistic factors in a second model of analysis (Table 1). The adjusted risk of adverse events within one year after atrial septal defect closure did not alter in the second model.

In our study, we obtained data from two of the Swedish paediatric cardiac centres, performing two-thirds of all percutaneous device closure and half of all paediatric heart surgeries, according to the 2017 annual rapport from the Swedish Registry of Congenital Heart Disease.40 One of the two interventional centres refers patients for surgery to the other centre. By this approach, a harmonisation concerning indications and choice of interventional method (surgery or percutaneous) is made and reduces the risk of selection biased due to method in this study.

Conclusion

Neonatal comorbidities were not associated with increased risk of major and minor adverse events after atrial septal defect closure. Children with neonatal pulmonary morbidity may be a selected group suffering from right-ventricular function impairment and reduced pulmonary capillary bed maturation, and a careful assessment and risk stratification can be advised in this group.
Children with symptomatic atrial septal defects have a two to four times increased risk of major events, predominantly peri-interventional arrhythmias, during or following an atrial septal defect closure, suggesting that a post-interventional follow-up with regard to arrhythmias should be considered in this group.

Acknowledgements. We would like to thank the Swedish Registry of Congenital Heart Disease register as well as Swedish Medical Birth Register and their steering committees for sharing data, and we acknowledge all the paediatric cardiologists and nurses in Sweden. Further, we also thank Annika Maxedius, Skåne University Lunds Hospital for her support.

Financial Support. This study was funded by the Unit of Research, Education and Development, Östersund Hospital, Region Jämtland Härjedalen.

Conflict of Interests. None.

Ethical Standards. The authors assure that all procedures contributing to this work is in adherence with the ethical standards of the Helsinki Declaration of 1975, as revised in 2008.

This study was approved by the Ethics Committee for Human Research at Umeå University (D-nr 2015-10-31M alteration 2015-88-32M), and informed consent was obtained by everyone in the study population or each guardian of the included children.

References

1. Hoffman JJ, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J 2004; 147: 425–439.
2. McDaniel NL, Ventricular and atrial septal defects. Pediatr Rev/Acad Pediatr 2001; 22 (8): 265–270.
3. Lammers A, Hager A, Eicken A, Lange R, Hauser M, Hess J. Need for closure of secundum atrial septal defect in infancy. J Thorac Cardiovasc Surg 2005; 129 (6): 1353–1357.
4. Feltes TF, Bacha E, Beekman RH, 3rd, et al. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation 2011; 123 (22): 2607–2652.
5. Baumgartner H, Bonhoeffer P, De Groot NM, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010; 31 (23): 2915–2957.
6. Morken NH, Kalen K, Hagberg B, Jacobsson B. Preterm birth in Sweden 1973–2001: rate, subgroups, and effect of changing patterns in multiple births, maternal age, and smoking. Acta Obstet Gynecol Scand 2005; 84 (6): 558–565.
7. Beck S, Woydyla D, Say L, et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. Bull World Health Organ 2010; 88 (1): 31–38.
8. Fellman V, Hellstrom-Westas L, Norman M, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009; 301 (21): 2225–2233.
9. Norman M, Hallberg B, Abrahamsson T, et al. Association between year of birth and 1-year survival among extremely preterm infants in Sweden during 2004–2007 and 2014–2016. JAMA 2019; 321 (12): 1188–1199.
10. Bensley JG, Stacy VK, De Matteo R, Harding R, Black MJ. Cardiac remodeling as a result of pre-term birth: implications for future cardiovascular disease. Eur Heart J 2010; 31 (16): 2058–2066.
11. Broadhouse KM, Finnemore AE, Price AN, et al. Cardiovascular magnetic resonance of cardiac function and myocardial mass in preterm infants: a preliminary study of the impact of patent ductus arteriosus. J Cardiovasc Magn Reson 2014; 16: 54.
12. Schubert U, Muller M, Abdul-Khaliq H, Norman M. Preterm birth is associated with altered myocardial function in infancy. J Am Soc Echocardiogr 2016; 29 (7): 670–678.
13. Lewandowski AJ, Augustine D, Lamata P, et al. Preterm heart in adult life: cardiovascular magnetic resonance reveals distinct differences in left ventricular mass, geometry, and function. Circulation 2013; 127 (2): 197–206.
14. Bishop RN, Everett AD, Ringel RE, et al. Device closure of secundum atrial septal defects in infants weighing less than 8 kg. Pediatr Cardiol 2014; 35 (7): 1124–1131.
15. Wood AM, Holzer RJ, Texter KM, et al. Transcatheter elimination of left-to-right shunts in infants with bronchopulmonary dysplasia is feasible and safe. Congenit Heart Dis 2011; 6 (4): 330–337.
16. Zaqout M, De Baets F, Schelstraete P, et al. Pulmonary function in children after surgical and percutaneous closure of atrial septal defect. Pediatr Cardiol 2010; 31 (8): 1171–1175.
17. Du ZD, Koenig P, Cao QL, Wright D, Hetischmidt M, Hijazi ZM. Comparison of transcatheter closure of secundum atrial septal defect using the Amplatzer septal occluder associated with deficient versus sufficient rims. Am J Cardiol 2002; 90 (8): 865–869.
18. UCR. National Quality Registry for Congenital Heart Disease, 2017. http://kvalitetsregister.se/englishpages/findaregistry/registerarkiv/english/nationalqualityregistryforcongenitalheartdiseasesweden.2279.html.
19. Socialstyrelsen. The Swedish Medical Birth Register, 2017. http://www.socialstyrelsen.se/registry/halsodatregister/medicinskafodelseregistret/en/english.
20. Torgoh J, Liuba P, Sjöberg G, Rydberg A, Naumburg E. Adverse events during 1 year after surgical and percutaneous closure of atrial septal defects in preterm children. Cardiol Young 2019; 29 (5): 626–636.
21. Masarone D, Valente F, Rubino M, et al. Pediatric heart failure: a practical guide to diagnosis and management. Pediatr Neonatol 2017; 58 (4): 303–312.
22. Kantor PF, Lougheed J, Dancia A, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol 2013; 29 (12): 1535–1552.
23. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation 2015; 132 (21): 2037–2099.
24. Sadiq M, Kazmi T, Rehman AU, Latifi F, Hyder N, Qureshi SA. Device closure of atrial septal defect: Medium-term outcome with special reference to complications. Cardiol Young 2012; 22 (1): 71–78.
25. Du ZD, Hijazi ZM, Kleinman CS, Silverman NH, Larnitz K. Comparison between transcatheter and surgical closure of secundum atrial septal defect in children and adults. J Am Coll Cardiol 2002; 39 (11): 1836–1844.
26. Nykansen DG, Forbes TJ, Du W, et al. CRISP: catheterization risk score for pediatrics: a report from the Congenital Cardiac Interventional Study Consortium (CCISC). Catheter Cardiovasc Inter 2016; 87 (2): 302–309.
27. Kim NK, Park SJ, Choi JY. Transcatheter closure of atrial septal defect: does age matter? Korean Circ J 2011; 41 (11): 633–638.
28. Wyss Y, Quandt D, Weber R, et al. Interventional closure of secundum type atrial septal defects in infants less than 10 kilograms: Indications and procedural outcome. J Interv Cardiol 2016; 29 (6): 646–653.
29. Butera G, Carminati M, Chessa M, et al. Percutaneous versus surgical closure of secundum atrial septal defect: comparison of early results and complications. Am Heart J 2006; 151 (1): 228–234.
30. Saleemi MS, El-Khufash A, Franklin O, Corcoran JD. Serial changes in myocardial function in preterm infants over a four week period: the effect of gestational age at birth - ScienceDirect. Early Hum Dev 2017; 90 (7): 349–352.
31. Levy PT, Patel MD, Choudhry S, Hamvvas A, Singh GK. Evidence of echocardiographic markers of pulmonary vascular disease in asymptomatic infants born preterm at one year of age. J Pediatr 2018; 197: 48–56.e2.
32. Diab KA, Cao QL, Bacha EA, Hijazi ZM. Device closure of atrial septal defects with the Amplatzer septal occluder: safety and outcome in infants. J Thorac Cardiovasc Surg 2007; 134 (4): 960–966.
33. Azhari N, Shihata MS, Al-Fatani A. Spontaneous closure of atrial septal defects within the oval fossa. Cardiol Young 2004; 14 (2): 148–155.
34. Shaddy RE, George AT, Jaekel T, et al. Systematic literature review on the incidence and prevalence of heart failure in children and adolescents. Pediatr Cardiol 2018; 39 (3): 415–436.
35. Cuypers JA, Opic P, Menting ME, et al. The unnatural history of an atrial septal defect: longitudinal 35 year follow up after surgical closure at young age. Heart 2013; 99 (18): 1346–1352.

36. Redington AN. Physiopathology of right ventricular failure. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2006; 9: 3–10.

37. Cnattingius S, Ericson A, Gunnarskog J, Kallen B. A quality study of a medical birth registry. Scand J Soc Med 1990; 18 (2): 143–148.

38. Bodell A, Björkhem G, Thilén U, Naumburg E. National quality register of congenital heart diseases – can we trust the data? J Congenit Cardiol 2017; 1 (1): 53.

39. Sperandei S. Understanding logistic regression analysis. Biochem Med (Zagreb) 2014; 24: 12–18.

40. Ulf Thilén GB, Jeremiasen I, Björkhem G, Bergman G. Nationellt register för medfödda hjärtsjukdomar, 2017. http://www.ucr.uu.se/swedcon/.